Development of an attenuated strain of chikungunya virus for use in vaccine production.
about
Antiviral perspectives for chikungunya virusNovel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanismProduction of Chikungunya Virus-Like Particles and Subunit Vaccines in Insect CellsCross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccineExtended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine CandidateChikungunya disease in nonhuman primates involves long-term viral persistence in macrophagesProbing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signalingA virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infectionChikungunya: epidemiologyCritical role for bone marrow stromal antigen 2 in acute Chikungunya virus infection.Utilization of an Eilat Virus-Based Chimera for Serological Detection of Chikungunya InfectionEarly Events in Chikungunya Virus Infection-From Virus Cell Binding to Membrane FusionDNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in micePrime-boost immunization strategies against Chikungunya virusResidue 82 of the Chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in miceChikungunya vaccines in developmentThe Global Virus Network: Challenging chikungunyaNonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model)Characterization of a Chikungunya virus strain isolated from banked patients' seraChimeric alphavirus vaccine candidates for chikungunyaA chikungunya fever vaccine utilizing an insect-specific virus platformChikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.Development of Vaccines for Chikungunya Fever.Animal Models of Chikungunya Virus Infection and Disease.Next generation sequencing of DNA-launched Chikungunya vaccine virus.Chikungunya: a potentially emerging epidemic?Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in miceChikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.Epidemiology, clinical manifestations, and diagnosis of Chikungunya fever: lessons learned from the re-emerging epidemic.A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.Replication cycle of chikungunya: a re-emerging arbovirus.Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein.Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.Expression of plasmid-based shRNA against the E1 and nsP1 genes effectively silenced Chikungunya virus replicationEffective chikungunya virus-like particle vaccine produced in insect cells.A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritisTransmission potential of two chimeric Chikungunya vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. albopictus.Serologic evidence of arboviral infections among humans in Kenya.Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype.
P2860
Q21284682-56AB4382-764D-4DCA-9561-0B683E47E008Q21559402-A6344203-CE93-4529-A21E-E5B2F9170DA2Q24261442-4E3F7529-6100-4E29-B4F5-7004C7113BDBQ24276414-9BDE1187-78F7-4755-92A0-44CAFF497E32Q24276430-6D89280C-3590-4497-92EB-8C1F100C12C3Q24288996-95967F95-0180-4717-A235-A47545FC24A5Q24608725-5B2C7695-58F5-49D9-BB0F-70B71CA76AC3Q24631774-902C3914-6780-4C01-A064-6E0954C667EFQ24701719-3FDBDD2D-269E-4761-8C27-7E0578F35F92Q24701738-5A17CF90-F6BB-4353-8516-43D1F48898FAQ24701740-E0A74E83-A0A3-4478-92EC-AFABA03DB897Q24701760-6ABBEDDB-156F-4DE6-8430-63F73F3EBAC4Q24701765-C69B2F5E-CFD7-4C54-8998-EAFC549798F7Q24701774-8A2E07BA-F4B4-4F3C-B40C-62EB1E3FB376Q24701776-ADAC1F4F-EE40-47C7-BB00-16F18BF70148Q26700081-D3985ABB-8766-4E1A-8320-FCD3D00E9A82Q26700155-D8B02015-1AEF-4A8D-AA99-379804502F2AQ26782722-3DBCF3AD-0E0B-406B-9EBA-9532A7BEC7D2Q26970814-748B1DFD-9506-4681-B4F9-3374C4EB6E39Q27487105-91A52EB3-71C5-4E51-9814-1DC72138E1DAQ28954709-E7CFAD10-8DB7-45BA-84BE-9BE4CFA64149Q30235512-1CFD23B1-78B4-4110-A357-132653B519E1Q30240191-DEEA2A00-464E-4D96-958E-AEC749E47608Q30240216-43A3B981-59F6-4A07-8EF7-D6831BBDA7FFQ30384231-F31009BF-1BD4-4118-A357-BB8F40CC3281Q30388754-984A6D14-FE8C-4A11-AB59-ACA086E374FEQ30516488-326A4D8B-2E23-469A-8587-76A2A4146D2DQ30938741-81C3DF7A-44A7-4A2C-94E2-D4A13672C4B2Q33684369-51DA03D7-03D6-4A54-8007-0AEC3C421D43Q33796693-9562541F-CA56-40E5-89C2-11F3039AF668Q33945612-EF3C7EF2-7837-4C24-BA1E-26CB05D674B2Q34042046-01FC5248-DF19-4A62-AA36-02146057CCFDQ34264257-25EEE3C1-35EA-4D04-9294-45FEB01AF797Q34394530-8EE01D1A-2112-4AB4-85E3-B07B039ADFEDQ34441412-E1DF7662-8CEA-41B2-BE88-0FE1460FEE13Q34630576-DC9A82CC-9D87-4CE7-B765-E94612084227Q34703785-74A44115-EE33-48C1-A4DD-803C3AD8C4BFQ35031851-2579D5E5-15B5-4619-8BC8-D8B2DEA9FC83Q35065642-5E6ECA04-1F2A-4246-B514-381A5F3C34FEQ35076889-FC7F97B6-E439-441D-BB3A-D30EA7FE4B74
P2860
Development of an attenuated strain of chikungunya virus for use in vaccine production.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh-hant
name
Development of an attenuated strain of chikungunya virus for use in vaccine production.
@en
Development of an attenuated strain of chikungunya virus for use in vaccine production.
@nl
type
label
Development of an attenuated strain of chikungunya virus for use in vaccine production.
@en
Development of an attenuated strain of chikungunya virus for use in vaccine production.
@nl
prefLabel
Development of an attenuated strain of chikungunya virus for use in vaccine production.
@en
Development of an attenuated strain of chikungunya virus for use in vaccine production.
@nl
P2093
P1433
P1476
Development of an attenuated strain of chikungunya virus for use in vaccine production.
@en
P2093
P304
P356
10.1016/0264-410X(86)90003-4
P407
P577
1986-09-01T00:00:00Z